Get the Stockscreener App
38.20
9.77%
3.40
After Hours:
37.72
-0.48
-1.26%
Corcept Therapeutics Inc stock is traded at $38.20, with a volume of 6.69M.
It is up +9.77% in the last 24 hours and down -52.70% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$34.80
Open:
$35.76
24h Volume:
6.69M
Relative Volume:
5.34
Market Cap:
$4.02B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
30.32
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-53.78%
1M Performance:
-52.70%
6M Performance:
-46.45%
1Y Performance:
-23.55%
1-Day Range:
$35.12
$38.44
1-Week Range:
$32.99
$82.98
52-Week Range:
$32.99
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
38.20 | 3.66B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-31-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-25 | Initiated | UBS | Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Fraud Investigation: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated (CORT) on Behalf of Shareholders - ACCESS Newswire
Why Is CORT Stock Falling Today? - Asianet Newsable
Synergy Asset Management LLC Raises Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Potential Securities Law Violations - FinancialContent
Levi & Korsinsky Investigates Corcept Therapeutics Incorporated (CORT) Over Potential Securities Fraud Allegations - ACCESS Newswire
Corcept setback as relacorilant filing for hypercortisolism is rejected - The Pharma Letter
Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism - Finviz
FDA rejects relacorilant for Cushing’s-related high blood pressure - Cushing's Disease News
Corcept Therapeutics (NASDAQ:CORT) Trading Up 9.7%Here's What Happened - MarketBeat
The FDA Just Snubbed Corcept Therapeutics. Should You Buy the Dip in CORT Stock or Stay Far Away - Barchart.com
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations - FinancialContent
Implied Volatility Surging for Corcept Stock Options - Yahoo Finance
Canaccord Genuity Adjusts Price Target for Corcept Therapeutics (CORT) | CORT Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Mind Medicine (MNMD) - The Globe and Mail
Ulta Beauty To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Given New $99.00 Price Target at Canaccord Genuity Group - MarketBeat
CORT ALERT: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated for Possible Securities Fraud Violations - ACCESS Newswire
Corcept Therapeutics stock price target lowered to $90 at H.C. Wainwright - Investing.com Canada
Corcept Therapeutics stock price target cut by Canaccord on FDA setback - Investing.com Canada
Corcept Therapeutics (CORT) Faces FDA Setback, But Growth Potent - GuruFocus
HC Wainwright & Co. Lowers Price Target for Corcept Therapeutics (CORT) | CORT Stock News - GuruFocus
FDA rejects drug for hormone disorder - medwatch.com
US FDA declines to approve Corcept's drug for rare hormonal disorder - Reuters
Kaplan Fox Announces an Investigation Into Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations - The National Law Review
Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT - ts2.tech
Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets - ts2.tech
A Risky Spot For Corcept Therapeutics (NASDAQ:CORT) - Seeking Alpha
What drives Corcept Therapeutics Incorporated stock priceTrading Psychology Tips & Build Wealth With Strategy - earlytimes.in
FDA says it needs additional evidence of effectiveness for Corcept relacorilant - Yahoo Finance
Stocks making big moves yesterday: FuelCell Energy, Corcept, and PacBio - TradingView — Track All Markets
The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56% - simplywall.st
Why We're Not Concerned Yet About Corcept Therapeutics Incorporated's (NASDAQ:CORT) 56% Share Price Plunge - 富途牛牛
Calamos Advisors LLC Decreases Stake in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT - ts2.tech
Why Corcept Therapeutics plummeted by 50% today - MSN
US FDA declines to approve Corcept’s drug for rare hormonal disorder - wibqam.com
Why Corcept Therapeutics Plummeted by 50% Today - The Globe and Mail
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension - ts2.tech
Why Corcept Therapeutics Plummeted by 50% Today - The Motley Fool
Why Corcept (CORT) Shares Are Falling Today - Finviz
Why Corcept Therapeutics stock crashed today and what comes next? - CryptoRank
Corcept stumbles after Cushing's drug met with FDA rebuff - FirstWord Pharma
Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations - NewMediaWire
Corcept Therapeutics price target lowered to $50 from $135 at Truist - TipRanks
Corcept Therapeutics Faces FDA Setback for Relacorilant Approval - TipRanks
Corcept Therapeutics Inc Receives FDA Complete Response Letter for Relacorilant - TradingView — Track All Markets
Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next - ts2.tech
Stock Traders Buy Large Volume of Put Options on Corcept Therapeutics (NASDAQ:CORT) - MarketBeat
Truist Securities Lowers Corcept Therapeutics' Price Target to $50 From $135, Buy Rating Kept - marketscreener.com
Truist Securities lowers Corcept Therapeutics stock price target on FDA concerns - Investing.com Nigeria
Corcept nosedives 48% after FDA rejected core drug - breakingthenews.net
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):